The Rising Cost of Developing Cardiovascular Therapies and Reproducibility in Translational Research: Do Not Blame It (All) on the Bench.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Achieving reproducibility in the innovation process.Open research Europe · 2025
   Article
2. High throughput screening system for engineered cardiac tissues.Frontiers in bioengineering and biotechnology · 2023
   Article
3. Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes.Scientific reports · 2020
   Article
4. Are Synthetic Data Derivatives the Future of Translational Medicine?JACC. Basic to translational science · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.